Ranitidine - instructions for use, analogs, reviews and release forms (tablets of 150 mg and 300 mg) of a drug for the treatment of stomach and duodenal ulcers, heartburn in adults, children and pregnancy

In this article, you can read the instructions for using the drug Ranitidine. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Ranitidine in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Ranitidine analogues in the presence of existing structural analogues. Use for treatment of stomach and duodenal ulcers, heartburn in adults, children, as well as during pregnancy and lactation.

Ranitidine - blocker of histamine H2-receptors.Reduces basal and stimulated secretion of hydrochloric acid, caused by irritation of baroreceptors, food load, action of hormones and biogenic stimulants (gastrin, histamine, pentagastrin). Ranitidine reduces the volume of gastric juice and the content of hydrochloric acid in it, increases the pH of the contents of the stomach, which leads to a decrease in the activity of pepsin. After oral administration in therapeutic doses does not affect the level of prolactin. Inhibits microsomal enzymes.

Duration of action after a single dose of up to 12 hours.

Pharmacokinetics

Quickly absorbed, eating does not affect the degree of absorption. When administered orally, the bioavailability of ranitidine is approximately 50%. Binding to plasma proteins does not exceed 15%. It is slightly metabolized in the liver with the formation of desmethylranitidine and S-oxide ranitidine. It is excreted mainly with urine (60-70%, unchanged - 35%), a small amount - with feces. Poorly penetrates the blood-brain barrier. Penetrates through the placenta. Excreted in breast milk (concentration in breast milk in women during lactation is higher than in plasma).

Indications

• treatment and prevention of exacerbations of peptic ulcer of the stomach and duodenum;
• stomach ulcers and duodenal ulcers associated with the intake of NSAIDs;
• reflux-esophagitis, erosive esophagitis;
• Zollinger-Ellleson syndrome;
• treatment and prevention of postoperative, "stressful" ulcers of the upper gastrointestinal tract;
• prevention of recurrent bleeding from the upper gastrointestinal tract;
• prevention of aspiration of gastric juice in operations under general anesthesia (Mendelssohn syndrome).

Forms of release

Tablets coated with 150 mg and 300 mg.

Instructions for use and reception scheme

Ranitidine is taken regardless of food intake, without chewing, squeezed with a small amount of liquid.

Stomach ulcer and duodenal ulcer. For treatment of exacerbations appoint 150 mg twice a day (morning and evening) or 300 mg at night. If necessary, 300 mg twice a day. The duration of the course of treatment is 4-8 weeks. To prevent exacerbations appoint 150 mg at night, for smokers - 300 mg at night.

Ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). Assign 150 mg twice a day or 300 mg per night for 8-12 weeks.Prevention of ulceration when taking NSAIDs - 150 mg 2 times a day.

Postoperative and "stressful" ulcers. Assign 150 mg twice a day for 4-8 weeks.

Erosive reflux esophagitis. Assign 150 mg twice a day or 300 mg at night. If necessary, the dose can be increased to 150 mg 4 times a day. The course of treatment is 8-12 weeks. Prolonged preventive therapy is 150 mg twice a day.

Zollinger-Ellison syndrome. The initial dose is 150 mg 3 times a day, if necessary, the dose can be increased.

Prevention of recurrent bleeding. 150 mg twice a day.

Prevention of the development of Mendelssohn syndrome. Assign a dose of 150 mg for 2 hours before anesthesia, and preferably 150 mg the night before.

If there is a concomitant liver function disorder, a dose reduction may be required.

Patients with renal insufficiency with CC less than 50 ml / min the recommended dose is 150 mg per day.

Side effect

• nausea, vomiting;
• dry mouth;
• constipation;
• diarrhea;
• abdominal pain;
• acute pancreatitis;
• leukopenia, thrombocytopenia, agranulocytosis, pancytopenia;
• lowering blood pressure;
• bradycardia;
• arrhythmia;
• atrio-ventricular block;
• increased fatigue;
• drowsiness;
• headache;
• dizziness;
• confusion of consciousness;
• noise in ears;
• irritability;
• hallucinations (mainly in elderly patients and severe patients);
• blurred vision;
• arthralgia;
• myalgia;
• hyperprolactinemia;
• gynecomastia;
• amenorrhea;
• decreased libido;
• impotence;
• hives;
• skin rash;
• angioedema;
• anaphylactic shock;
• bronchospasm;
• alopecia.

Contraindications

• pregnancy;
• lactation;
• children's age till 12 years;
• increased sensitivity to ranitidine or other components of the drug.

special instructions

Treatment with ranitidine may mask the symptoms associated with carcinoma of the stomach, so before starting treatment it is necessary to exclude the presence of cancer-ulcers.

Ranitidine, like all H2-gistaminoblokatory, undesirably abruptly cancel (syndrome "bounce").

With long-term treatment of weakened patients under stress, bacterial lesions of the stomach are possible with the subsequent spread of infection.

There is evidence that ranitidine can cause acute attacks of porphyria.

Blockers of H2-histamine receptors should be taken 2 hours after taking Itraconazole or Ketoconazole in order to avoid a significantreducing their absorption.

It can be the cause of a false positive response to a sample of protein in the urine.

The blockers of H2-histamine receptors can counteract the effects of pentagastrin and histamine on the acid-forming function of the stomach, therefore, it is not recommended to use H2-histamine-receptor blockers within 24 hours preceding the test.

Blockers of H2-histamine receptors can suppress the skin reaction to histamine, thus leading to false positive results (it is recommended to stop the use of H2-histamine receptor blockers before conducting diagnostic skin tests to detect an allergic skin reaction of immediate type).

During treatment, avoid eating foods, beverages and other medications that can cause irritation of the gastric mucosa.

Impact on the ability to drive vehicles and manage mechanisms

During the treatment period, it is necessary to refrain from engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.

Drug Interactions

Smoking reduces the effectiveness of ranitidine.

Increases the concentration of Metoprolol in the blood serum (by 80% and 50%, respectively), while the half-life of metoprolol increases from 4.4 to 6.5 h.

Due to the increase in the pH of the contents of the stomach with simultaneous intake may decrease the absorption of itraconazole and ketoconazole.

Inhibits the metabolism in the liver of phenazone, aminophenazone, diazepam, hexobarbital, propranolol, diazepam, lidocaine, phenytoin, theophylline, aminophylline, indirect anticoagulants, glipizide, butformin, metronidazole, calcium antagonists.

Drugs that depress the bone marrow increase the risk of neutropenia.

When used simultaneously with antacids, sucralfate in high doses, it is possible to slow the absorption of ranitidine, so a break between taking these drugs should be at least 2 hours.

Analogues of the drug ranitidine

Structural analogs for the active substance:

• Acidex;
• Acyl;
• Gertokalm;
• Gistak;
• Zantak;
• Zantyn;
• Zoran;
• Raniberle 150;
• Ranigast;
• Ranisan;
• Ranital;
• Ranitidin Sediko;
• Ranitidin Sopharma;
• Ranitidine Akos;
• Ranitidine Acry;
• Ranitidine-LekT;
• Ranitidine-Ferein;
• Ranitidine hydrochloride;
• Ranitin;
• Rantak;
• Ranks;
• Ulkodin;
• Ulkosan;
• Ullran.

Similar medicines:

Other medicines: